REBLOZYL® (luspatercept-aamt) for the Treatment of Anaemia Associated with Beta-Thalassemia
REBLOZYL® (luspatercept-aamt) is administered through a subcutaneous injection with a starting dose of 1mg/kg. Credit: Celgene Corporation.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more